AR112341A1 - ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG - Google Patents
ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgGInfo
- Publication number
- AR112341A1 AR112341A1 ARP180102027A AR112341A1 AR 112341 A1 AR112341 A1 AR 112341A1 AR P180102027 A ARP180102027 A AR P180102027A AR 112341 A1 AR112341 A1 AR 112341A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Los anticuerpos biespecificos son útiles para tratar varias enfermedades autoinmunes, incluyendo la enfermedad inflamatoria del intestino, tales como la enfermedad de Crohn y colitis ulcerosa, psoriasis, artritis psoriásica e hidradenitis supurativa. Reivindicación 1: Anticuerpo biespecífico de inmunoglobulina G (IgG), caracterizado porque comprende, a) una primera cadena pesada (HC1) que comprende una región variable de cadena pesada (HCVR1), en donde HCVR1 comprende regiones determinantes de complementariedad de cadena pesada (HCDR) 1, 2 y 3, en donde la secuencia de aminoácido de HCDR1 es la SEC ID Nº 13, la secuencia de aminoácidos de HCDR2 es la SEC ID Nº 14 y la secuencia de aminoácidos de HCDR3 es la SEC ID Nº 15; b) una primera cadena ligera (LC1) que comprende una región variable de cadena ligera (LCVR1), en donde LCVR1 comprende regiones determinantes de complementariedad de cadena ligera (LCDR) 1, 2 y 3, en donde la secuencia de aminoácidos de LCDR1 es la SEC ID Nº 16, la secuencia de aminoácidos de LCDR2 es la SEC ID Nº 17 y la secuencia de aminoácidos de LCDR3 es la SEC ID Nº 18; c) una segunda cadena pesada (HC2) que comprende una región variable de cadena pesada (HCVR2), en donde HCVR2 comprende las HCDRs 4, 5 y 6, en donde la secuencia de aminoácidos de HCDR4 es la SEC ID Nº 19, la secuencia de aminoácidos de HCDR5 es la SEC ID Nº 20 y la secuencia de aminoácidos de HCDR6 es la SEC ID Nº 21, y d) una segunda cadena ligera (LC2) que comprende una región variable de cadena ligera (LCVR2), en donde LCVR2 comprende las LCDRs 4, 5 y 6, en donde la secuencia de aminoácidos de LCDR4 es la SEC ID Nº 22, la secuencia de aminoácidos de LCDR5 es la SEC ID Nº 23 y la secuencia de aminoácidos de LCDR6 es la SEC ID Nº 24, en donde HC1 forma por lo menos un enlace disulfuro entre cadenas con LC1, HC2 forma por lo menos un enlace disulfuro entre cadenas con LC2, y la HC1 forma por lo menos dos enlaces disulfuro entre cadenas con HC2, y en donde el anticuerpo biespecifico IgG se une a TNF a humano (TNFa) y a la subunidad p19 de IL-23 humana (IL23p19).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540182P | 2017-08-02 | 2017-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112341A1 true AR112341A1 (es) | 2019-10-16 |
Family
ID=63165523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102027 AR112341A1 (es) | 2017-08-02 | 2018-07-19 | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190040156A1 (es) |
| AR (1) | AR112341A1 (es) |
| TW (1) | TW201917135A (es) |
| WO (1) | WO2019027780A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| BR112022009799A2 (pt) | 2019-12-06 | 2022-08-16 | Ablynx Nv | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 |
| AR123477A1 (es) * | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
| WO2024061288A1 (en) * | 2022-09-21 | 2024-03-28 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Antibodies targeting tnf alpha and il-23 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ES2707152T3 (es) * | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PL1937721T3 (pl) | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
-
2018
- 2018-07-19 AR ARP180102027 patent/AR112341A1/es unknown
- 2018-07-20 TW TW107125099A patent/TW201917135A/zh unknown
- 2018-07-26 WO PCT/US2018/043827 patent/WO2019027780A1/en active Application Filing
- 2018-07-26 US US16/046,282 patent/US20190040156A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019027780A1 (en) | 2019-02-07 |
| US20190040156A1 (en) | 2019-02-07 |
| TW201917135A (zh) | 2019-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112341A1 (es) | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG | |
| AR102417A1 (es) | Anticuerpos biespecíficos anti-tnf- / anti-il-23 | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
| CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| AR123912A2 (es) | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |